SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-1.04%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$541M
AUM Growth
+$541M
(-11%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-4.49%
Top 10 Holdings %
Top 10 Hldgs %
32.22%
Holding
125
New
17
Increased
28
Reduced
37
Closed
22
Top Buys
| 1 |
Alphabet (Google) Class C
GOOG
|
$8.28M |
| 2 |
Annexon
ANNX
|
$6.38M |
| 3 |
Ormat Technologies
ORA
|
$5.35M |
| 4 |
Eledon Pharmaceuticals
ELDN
|
$5.17M |
| 5 |
SolarEdge
SEDG
|
$5.1M |
Top Sells
| 1 |
Apple
AAPL
|
$14.2M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$12.4M |
| 3 |
Amazon
AMZN
|
$9.43M |
| 4 |
SentinelOne
S
|
$6.62M |
| 5 |
Nice
NICE
|
$6.09M |
Sector Composition
| 1 | Healthcare | 74.91% |
| 2 | Technology | 16.21% |
| 3 | Communication Services | 3.96% |
| 4 | Consumer Discretionary | 2.54% |
| 5 | Utilities | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Scholar Rock
SRRK
$3.31B
| $3.9M | 0.7% |
90,193
-76,673
| -46% | -$3.31M |
|
52
Travere Therapeutics
TVTX
$1.69B
| $3.84M | 0.7% |
+220,700
| New | +$3.84M |
|
53
enGene Holdings
ENGN
$234M
| $3.72M | 0.67% |
+560,000
| New | +$3.72M |
|
54
Savara
SVRA
$591M
| $3.72M | 0.67% |
1,211,533
+648,426
| +115% | +$1.99M |
|
55
Arrowhead Research
ARWR
$3.72B
| $3.71M | 0.67% |
+197,550
| New | +$3.71M |
|
56
Janux Therapeutics
JANX
$1.37B
| $3.66M | 0.66% |
+68,333
| New | +$3.66M |
|
|
ACOG
57
Alpha Cognition Inc. Common Stock
ACOG
$132M
| $3.65M | 0.66% |
+620,000
| New | +$3.65M |
|
|
SWTX
58
DELISTED
SpringWorks Therapeutics
SWTX
| $3.61M | 0.65% |
+100,000
| New | +$3.61M |
|
59
Biogen
BIIB
$20.8B
| $3.48M | 0.63% |
22,738
-1,717
| -7% | -$263K |
|
60
Enphase Energy
ENPH
$4.91B
| $3.45M | 0.62% |
50,198
-14,026
| -22% | -$963K |
|
61
Rocket Pharmaceuticals
RCKT
$351M
| $3.42M | 0.62% |
271,792
+40,000
| +17% | +$503K |
|
|
INZY
62
DELISTED
Inozyme Pharma
INZY
| $3.3M | 0.6% |
1,191,140
| – | – |
|
63
Camtek
CAMT
$3.48B
| $2.93M | 0.53% |
36,287
| – | – |
|
64
Jasper Therapeutics
JSPR
$44.9M
| $2.9M | 0.52% |
135,720
-53,550
| -28% | -$1.14M |
|
65
Corvus Pharmaceuticals
CRVS
$437M
| $2.68M | 0.48% |
+500,491
| New | +$2.68M |
|
|
CRGX
66
DELISTED
CARGO Therapeutics
CRGX
| $2.59M | 0.47% |
179,674
-10,832
| -6% | -$156K |
|
67
Workday
WDAY
$62.5B
| $2.58M | 0.47% |
10,000
+2,500
| +33% | +$645K |
|
|
VIGL
68
DELISTED
Vigil Neuroscience
VIGL
| $2.55M | 0.46% |
1,502,429
-145,175
| -9% | -$247K |
|
69
Nutrien
NTR
$27.7B
| $2.5M | 0.45% |
55,894
+15,164
| +37% | +$679K |
|
70
Cullinan Oncology
CGEM
$443M
| $2.5M | 0.45% |
205,000
+19,129
| +10% | +$233K |
|
71
Pfizer
PFE
$141B
| $2.39M | 0.43% |
90,000
| – | – |
|
72
VistaGen Therapeutics
VTGN
$109M
| $2.39M | 0.43% |
808,550
| – | – |
|
73
Mineralys Therapeutics
MLYS
$1.91B
| $2.35M | 0.42% |
190,672
-81,800
| -30% | -$1.01M |
|
74
Ionis Pharmaceuticals
IONS
$9.63B
| $2.23M | 0.4% |
63,821
| – | – |
|
75
Ventyx Biosciences
VTYX
$181M
| $2.22M | 0.4% |
1,012,749
| – | – |
|